Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

˜The œLancet. Gastroenterology & hepatology

Topics

Medicine

Cancer Oncology

Internal Medicine

Surgery

Gastroenterology

Show all topics

DOI

10.1016/s2468-1253(21)00196-5